A venture capital firm based in Shenzhen, China was founded in the 1990s and currently has about 1.5 billion RMB in assets under management. The firm is currently investing out of their $30 million USD fund. The firm focuses on Series A-B deals within the USA, Canada, and China and typically invests $2-5 million USD per deal. The firm typically co-invests, but is willing to lead in specific situations.
The firm is opportunistic within the therapeutics and medical technology domains. However, for therapeutics, the firm focuses mostly on assets that are currently in Phase I or Phase II clinical trials. For Medical Devices, they prefer technologies that already have 510k or PMA clearance. Most importantly though, when investing, the firm requires that the technology has strong clinical evidence of efficacy. Strong evidence of efficacy is the most important criteria for the firm when investing in therapeutics and medical technology.
The firm is looking for a management team with a strong history of success as serial entrepreneurs or with strong clinical backgrounds. For investment opportunities without FDA clearance, the firm prefers seeing management teams with prior success in achieving FDA approval or candidates who have strong background from big pharma.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment